Han Dong, Shah Aakash, Awad Morcos A, Wu Zhongjun J, Griffith Bartley P
Department of Surgery, University of Maryland School of Medicine, 10 South Pine Street, MSTF 436, Baltimore, MD, 21201, USA.
Fischell Department of Bioengineering, A. James Clark School of Engineering, University of Maryland, College Park, MD, USA.
Appl Eng Sci. 2022 Jun;10. doi: 10.1016/j.apples.2022.100093. Epub 2022 Mar 7.
Extracorporeal membrane oxygenation (ECMO) is a modality of life support for patients suffering from respiratory and/or cardiac failure. With the advances in membrane oxygenation and pump technology in the last two decades, ECMO has become safer and more durable for clinical use. Along with its overall use, there has been an increase in patients who require long-term ECMO support; either awaiting lung recovery or transplantation. Many of them are awake, participating in physical rehabilitation, and even ambulating while supported on ECMO. While the broader ECMO experience is applied to bed-restricted and mechanically ventilated patients, contemporary studies demonstrated that the artificial respiration provided by ECMO is compatible with freedom from adjunctive mechanical ventilation, ambulation, and exercise. With this in mind, our group set out to develop a novel ambulatory ECMO system to facilitate ambulation in patients supported on ECMO. This paper gives a brief overview of the development of this system, focusing on the journey from a laboratory concept to approval for clinical use by the Food and Drug Administration.
体外膜肺氧合（ECMO）是一种为患有呼吸和/或心力衰竭的患者提供生命支持的方式。随着过去二十年间膜氧合和泵技术的进步，ECMO在临床应用中变得更安全、更耐用。随着其总体应用的增加，需要长期ECMO支持的患者也有所增多；这些患者要么等待肺恢复，要么等待肺移植。他们中的许多人在接受ECMO支持时是清醒的，参与身体康复，甚至能够行走。虽然更广泛的ECMO经验适用于卧床受限且接受机械通气的患者，但当代研究表明，ECMO提供的人工呼吸与无需辅助机械通气、行走和运动是相容的。考虑到这一点，我们团队着手开发一种新型的可移动ECMO系统，以方便接受ECMO支持的患者行走。本文简要概述了该系统的开发过程，重点介绍了从实验室概念到获得美国食品药品监督管理局批准用于临床的历程。
